134 related articles for article (PubMed ID: 1651826)
21. Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital.
Ena J; Houston A; Wenzel RP; Jones RN
J Chemother; 1993 Feb; 5(1):17-21. PubMed ID: 8459260
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of teicoplanin and vancomycin disk susceptibility tests.
Barry AL; Thornsberry C; Jones RN
J Clin Microbiol; 1986 Jan; 23(1):100-3. PubMed ID: 2939101
[TBL] [Abstract][Full Text] [Related]
23. Macrolides resistance of common bacteria isolated from Taiwan.
Chang SC; Chen YC; Luh KT; Hsieh WC
Diagn Microbiol Infect Dis; 1995 Dec; 23(4):147-54. PubMed ID: 9407220
[TBL] [Abstract][Full Text] [Related]
24. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
Van der Auwera P; Grenier P; Klastersky J
J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
Jensen KT; Schønheyder H; Pers C; Thomsen VF
APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
[TBL] [Abstract][Full Text] [Related]
26. Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States.
Cormican MG; Erwin ME; Jones RN
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):241-8. PubMed ID: 9458981
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.
Chin NX; Gu JW; Neu HC
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):685-91. PubMed ID: 2226499
[TBL] [Abstract][Full Text] [Related]
28. LY146032: activity and resistance development in vitro.
Mouton RP; Mulders SL
J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
[TBL] [Abstract][Full Text] [Related]
29. The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
King A; Phillips I
J Antimicrob Chemother; 2001 Aug; 48(2):219-23. PubMed ID: 11481291
[TBL] [Abstract][Full Text] [Related]
30. Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.
Rodriguez MJ; Snyder NJ; Zweifel MJ; Wilkie SC; Stack DR; Cooper RD; Nicas TI; Mullen DL; Butler TF; Thompson RC
J Antibiot (Tokyo); 1998 Jun; 51(6):560-9. PubMed ID: 9711219
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.
Fass RJ
Antimicrob Agents Chemother; 1991 Mar; 35(3):553-9. PubMed ID: 1903912
[TBL] [Abstract][Full Text] [Related]
32. The antibacterial action of vancomycin.
Watanakunakorn C
Rev Infect Dis; 1981; 3 suppl():S210-5. PubMed ID: 6805065
[TBL] [Abstract][Full Text] [Related]
33. Glycopeptide carboxamides active against vancomycin-resistant enterococci.
Zweifel MJ; Snyder NJ; Cooper RD; Nicas TI; Mullen DL; Butler TF; Rodriguez MJ
J Antibiot (Tokyo); 2003 Mar; 56(3):289-95. PubMed ID: 12760685
[TBL] [Abstract][Full Text] [Related]
34. Resistance to vancomycin and teicoplanin: an emerging clinical problem.
Johnson AP; Uttley AH; Woodford N; George RC
Clin Microbiol Rev; 1990 Jul; 3(3):280-91. PubMed ID: 2143434
[TBL] [Abstract][Full Text] [Related]
35. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
36. [Teicoplanin and vancomycin susceptibility in Staphylococcus aureus and coagulase-negative staphylococci].
Caiaffa Filho HH; Lima Mde P; Sinto SI; Andriolo A; Mendes CM
Rev Assoc Med Bras (1992); 1994; 40(2):77-80. PubMed ID: 7820154
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of teichomycin compared with those of other antibiotics.
Neu HC; Labthavikul P
Antimicrob Agents Chemother; 1983 Sep; 24(3):425-8. PubMed ID: 6227282
[TBL] [Abstract][Full Text] [Related]
38. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium.
Leclercq R; Derlot E; Weber M; Duval J; Courvalin P
Antimicrob Agents Chemother; 1989 Jan; 33(1):10-5. PubMed ID: 2523687
[TBL] [Abstract][Full Text] [Related]
39. The bactericidal activity of ampicillin, daptomycin, and vancomycin against ampicillin-resistant Enterococcus faecium.
el-Mady A; Mortensen JE
Diagn Microbiol Infect Dis; 1991; 14(2):141-5. PubMed ID: 1651825
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
Rolston KV; Wang W; Nesher L; Shelburne SA; Prince RA
J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
